Open AccessGNAQ T96S mutation abrogates the ability of wild‐type GNAQ to induce apoptosis by phosphorylating annexin A2 in natural killer/T cell lymphoma
Author(s) -
Zhao Wugan,
Zhang Min,
Wang Guannan,
Liu Enjie,
Jiang Guozhong,
Zhang Yanping,
Zhang Dandan,
Jian Xiangyu,
Zhao Haiyu,
Zhang Chongli,
Li Wencai
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15333
Subject(s) - gnaq , cancer research , annexin , biology , apoptosis , phosphorylation , mutation , microbiology and biotechnology , genetics , gene
Our previous study identified annexin A2 (ANXA2) as a Gaq‐interacting partner in natural killer/T cell lymphoma (NKTCL) cells transfected with the GNAQ T96S mutation vector by immunoprecipitation and mass spectrometry; however, the detailed molecular mechanisms by which GNAQ T96S might regulate ANXA2 remain to be defined in NKTCL. Herein, we found that the GNAQ T96S mutation significantly promotes the phosphorylation of ANXA2 at the Y24 site, whereas phosphorylation of ANXA2 abolishes the ability of WT GNAQ to trigger cell apoptosis. Further investigation revealed that a GNAQ T96S peptide inhibitor induced apoptosis by competing with ANXA2 binding to GNAQ T96S in NKTCL cells. In vivo animal experiments showed that a GNAQ T96S peptide inhibitor suppresses the growth of NKTCL cells carrying the GNAQ T96S mutation. Our current data suggest a role for GNAQ T96S/Src/ANXA2 in mediating the apoptosis of NKTCL cells, and the GNAQ T96S peptide could be a promising agent for therapy in NKTCL patients.